Curatis and Neupharma Secure Exclusive Licensing Deal for Corticorelin in Japan

Curatis Holding AG and Neupharma have announced an exclusive agreement to develop and market corticorelin for peritumoral brain edema (PTBE) in Japan. This strategic partnership involves upfront and milestone payments of up to CHF 83.5 million, with royalties up to 20% on sales. Neupharma will handle clinical trials in Japan, aiming for approval by conducting a pivotal study scheduled to begin in 2027.

Approximately 60,000 patients in Japan could benefit from corticorelin, addressing a significant unmet medical need, as no targeted therapies currently exist for PTBE. The global market for corticorelin, driven by its potential to reduce steroid use in PTBE treatment, might exceed USD 1 billion annually.

Corticorelin, an investigational drug, has shown promise in reducing debilitating side effects associated with existing PTBE treatments. Its development aligns with Curatis' focus on rare diseases and specialty care.